ETF Holdings Breakdown of CLDX

Stock Name	Celldex Therapeutics Inc
Ticker	CLDX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US15117B2025

CLDX institutional holdings

The following institutional investment holdings of CLDX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 48,142 USD 1,291,650

2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 40,572 USD 1,088,547 -1.9%

2025-10-17 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 4,343 USD 116,523 -1.9%

Total = 93,057 USD 2,496,720
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	48,142	USD 1,291,650
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	40,572	USD 1,088,547 -1.9%
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	4,343	USD 116,523 -1.9%
Total =	93,057	USD 2,496,720

News associated with CLDX

Wells Fargo & Company Has Lowered Expectations for Celldex Therapeutics (NASDAQ:CLDX) Stock Price: Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its price target decreased by investment analysts at Wells Fargo & Company from $44.00 to $38.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price points to a potential upside […] - 2025-08-22 02:46:53
HC Wainwright Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $42.00: Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its price objective reduced by HC Wainwright from $50.00 to $42.00 in a report issued on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other analysts have also recently issued reports about the company. The Goldman Sachs Group dropped their price objective on […] - 2025-08-21 05:18:49
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down Following Analyst Downgrade: Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) shares gapped down before the market opened on Wednesday after Wells Fargo & Company lowered their price target on the stock from $44.00 to $38.00. The stock had previously closed at $24.02, but opened at $21.96. Wells Fargo & Company currently has an overweight rating on the […] - 2025-08-21 02:26:55
Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $50.11: Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to […] - 2025-08-13 03:14:49
Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX): Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,834 shares of the biopharmaceutical company’s stock, valued at approximately $269,000. Other […] - 2025-08-05 04:32:52
GSA Capital Partners LLP Acquires New Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX): GSA Capital Partners LLP acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) in the 1st quarter, HoldingsChannel reports. The firm acquired 62,326 shares of the biopharmaceutical company’s stock, valued at approximately $1,131,000. A number of other hedge funds and other institutional investors have also made changes to their positions […] - 2025-07-31 04:34:49
Celldex Therapeutics (NASDAQ:CLDX) Share Price Passes Above 200-Day Moving Average – Should You Sell?: Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $21.24 and traded as high as $22.37. Celldex Therapeutics shares last traded at $21.98, with a volume of 978,039 shares traded. Wall […] - 2025-07-04 04:53:50
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $50.11 Average Target Price from Analysts: Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating […] - 2025-06-24 02:16:45
Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from HC Wainwright: HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research report released on Friday,Benzinga reports. The brokerage currently has a $50.00 price objective on the biopharmaceutical company’s stock. A number of other equities analysts also recently weighed in on CLDX. Morgan Stanley cut their price target on […] - 2025-06-16 03:10:51
Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $53.90: Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) have received an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy […] - 2025-05-30 03:06:55
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.: MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 9.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 42,771 shares of the biopharmaceutical company’s stock after acquiring an additional 3,830 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in […] - 2025-05-26 04:48:57
Northern Trust Corp Buys 34,885 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX): Northern Trust Corp increased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 6.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 597,605 shares of the biopharmaceutical company’s stock after purchasing an additional 34,885 shares during the period. Northern Trust Corp’s holdings in […] - 2025-05-16 04:38:55
The Goldman Sachs Group Lowers Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00: Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its price target decreased by The Goldman Sachs Group from $36.00 to $31.00 in a research report sent to investors on Friday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical company’s stock. A number of other analysts have also commented on the company. […] - 2025-05-12 02:58:50
Tudor Investment Corp ET AL Takes Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX): Tudor Investment Corp ET AL purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 32,545 shares of the biopharmaceutical company’s stock, valued at approximately $822,000. Other hedge […] - 2025-05-08 05:26:55
Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $55.30: Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy […] - 2025-05-05 02:35:00
Barclays PLC Increases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX): Barclays PLC grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 9.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 142,914 shares of the biopharmaceutical company’s stock after buying an additional 12,533 shares during the period. Barclays PLC […] - 2025-04-29 05:19:03
JPMorgan Chase & Co. Acquires 43,470 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX): JPMorgan Chase & Co. grew its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 103.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 85,545 shares of the biopharmaceutical company’s stock after buying an additional 43,470 shares during the quarter. JPMorgan […] - 2025-04-24 04:14:49
Renaissance Technologies LLC Makes New $3.45 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX): Renaissance Technologies LLC bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 136,588 shares of the biopharmaceutical company’s stock, valued at approximately $3,452,000. Renaissance Technologies LLC owned about 0.21% […] - 2025-04-23 04:37:03
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Geode Capital Management LLC: Geode Capital Management LLC cut its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 0.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,534,916 shares of the biopharmaceutical company’s stock after selling 5,597 shares during the quarter. Geode Capital […] - 2025-04-16 04:40:52
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts: Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation […] - 2025-04-07 03:06:58
American Century Companies Inc. Raises Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX): American Century Companies Inc. raised its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 46.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 608,457 shares of the biopharmaceutical company’s stock after purchasing an additional 193,093 […] - 2025-04-01 05:38:51
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages: Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-03-13 04:20:51
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month Low Following Analyst Downgrade: Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) shares hit a new 52-week low on Monday after The Goldman Sachs Group lowered their price target on the stock from $42.00 to $36.00. The Goldman Sachs Group currently has a neutral rating on the stock. Celldex Therapeutics traded as low as $19.66 and last traded at […] - 2025-03-05 04:55:05
Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $36.00 at The Goldman Sachs Group: Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its target price cut by The Goldman Sachs Group from $42.00 to $36.00 in a report released on Monday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” […] - 2025-03-04 06:26:51

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.